Repare Therapeutics Inc (OQ:RPTX)

Sep 09, 2020 07:00 am ET
Repare Therapeutics to Participate at Morgan Stanley Annual Global Healthcare Conference
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that Lloyd M. Segal, President and Chief Executive Officer, will participate in a virtual fireside chat at the Morgan Stanley Annual Global Healthcare Conference on Tuesday, September 15 at 10:15 a.m. ET.
Aug 13, 2020 04:05 pm ET
Repare Therapeutics Reports Second Quarter 2020 Financial Results and Operational Highlights
Repare Therapeutics Inc. (“Repare”) (Nasdaq: RPTX), a leading precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today reported financial results for the second quarter ended June 30, 2020, as well as recent operational highlights.
Jul 29, 2020 06:00 am ET
Repare Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Trial of RP-3500
“The TRESR (Treatment Enabled by SNIPRx) study of RP-3500 as a monotherapy or in combination with talazoparib is a promising targeted approach for a range of difficult-to-treat cancers in patients with tumors harboring genetic alterations we have identified and we believe could predict response,” said Lloyd M. Segal, President and Chief Executive Officer of Repare. “The RP-3500 development plan reflects our strategy to develop differentiated oncology treatments in highly targeted tumors.”
Jun 23, 2020 04:05 pm ET
Repare Therapeutics Announces Closing of Upsized Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
Repare Therapeutics Inc. (Nasdaq: RPTX), a leading precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced the closing of its previously announced upsized initial public offering of 12,650,000 of its common shares, including the exercise in full of the underwriters’ option to purchase up to an additional 1,650,000 common shares, at a public offering price of $20.00 per share. The gross proceeds to Repare, before deducting underwriting commissions and offering expenses, were $253.0 million. All of
Jun 18, 2020 09:56 pm ET
Repare Therapeutics Announces Pricing of Upsized Initial Public Offering
Repare Therapeutics Inc. (Nasdaq: RPTX), a leading precision oncology company enabled by our proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced the pricing of its upsized initial public offering of 11,000,000 of its common shares at a public offering price of $20.00 per share. The gross proceeds to Repare, before deducting underwriting commissions and offering expenses, are expected to be approximately $220.0 million. All of the common shares are being offered by Repare. In addition, Repare has granted the underwriters a 30-day opti

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.